News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Votes Against NDA For Boehringer Ingelheim Corporation's 'Female Viagra' Flibanserin


6/28/2010 4:28:58 PM

StockMarketsReview.com -- A U.S. Food and Drug Administration panel on Friday unanimously opposed Germany's Boehringer Ingelheim Pharmaceuticals, Inc.'s new drug application for Flibanserin 100 mg tablet for the proposed indication for treatment of hypo-active sexual desire disorder or HSDD, in premenopausal women. The panel voted 11-to-0 against the drugs approval.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES